Limb girdle muscular dystrophy (LGMD) type 2G is a rare form of muscle disease, described only in a few patients worldwide, caused by mutations in TCAP gene, encoding the protein telethonin. It is characterised by proximal limb muscle weakness associated with distal involvement of lower limbs, starting in the first or second decade of life.
Introduction
Telethonin (or titin-cap) is a 19 kDa protein, consisting of 167 amino acids, encoded by the TCAP gene, which includes two exons and maps on chromosome 17q12 [1] . It is one of the most abundant transcripts in skeletal muscle and localizes to the Z-line of sarcomere in adult skeletal and cardiac muscles [2] . The protein is involved in normal sarcomere assembly and development, as well as in sarcomere-membrane interaction and signalling [1] . It interacts with the titin N-terminus, joining two antiparallel titin (Z1-Z2) domains together, and with other Z-disc proteins, such as LIM protein, Ankyrin Repeat Domain 2 protein, myostatin, potassium channel B subunit minK, protein kinase D and murine double minute 2. In the TCAP null mouse and in patients without telethonin expression [3, 4] , the sarcomere architecture is generally normal. Pathogenesis seems to be related to disruption of sarcomere-T-tubular interaction, as shown in zebrafish models [5] .
Mutations in the TCAP gene are responsible primarily for limb girdle muscular dystrophy 2G (OMIM 601954). Until now, only few families affected by LGMD2G have been described [Table 1A -B].
LGMD2G is an extremely rare disease, originally described in the Brazilian population [4, [6] [7] [8] [9] and subsequently reported in patients originating from China [10, 11] , Moldavia [12] , Portugal [13] , India [14] [15] [16] , Spain [17] and Turkey [18] .
LGMD2G phenotype is characterised by proximal limb muscles weakness associated with distal involvement of lower limbs with foot-drop. Atrophy generally involves muscles of thighs and the anterior compartment of the legs. Symptoms generally start in the first or second decade of life with lower limbs weakness. The disease is slowly progressive with 40% of patients losing independent ambulation by the fourth decade. Calf hypertrophy and scapular winging are described in some patients; less frequently, contractures of Achilles tendons can occur. Creatine Kinase (CK) levels are usually increased (3-30×). Cardiac involvement is described only in a few cases [6] and pulmonary function is usually normal. Muscle biopsy shows dystrophic features, sometimes associated with rimmed vacuoles. At immunostaining for telethonin, both partial reduction and absence of the protein were described.
Mutations in TCAP gene can also be responsible for other clinical phenotypes. Recessive homozygous mutations have been reported in a few cases of Congenital Muscular Dystrophy [19] [20] [21] , and autosomal dominant missense mutations were described in patients with dilated and hypertrophic cardiomyopathy [22] . Patients with LGMD2G skeletal muscle phenotype mainly harbour frameshift or nonsense mutations with an autosomal recessive pattern of inheritance.
Case report
A 28-year-old woman from Thessaly, Greece presented to medical attention for slowly progressive lower limb muscle weakness and atrophy.
Her parents were third grade cousins. No family history of muscular disorders was detected, except for a sister of the grandfather with mild ambulatory difficulties. Birth and psychomotor development were normal; in adolescence, she even practiced martial arts.
Symptoms started at 17 years of age with generalized muscle weakness and difficulties in walking and climbing stairs. Clinical evaluation, performed at age 28, revealed weakness and atrophy of the lower limbs, with major involvement of distal muscles (strength according to along withhyperlordosis and needed a wheelchair to cover longer distances. She was not able to walk on heels and toes. Muscle MRI of the lower limbs, performed at age 37, demonstrated diffuse and severe fibro-fatty substitution and atrophy of lower limbs muscle associated with a relative sparing of vastus lateralis, sartorius and soleus muscles (Fig. 1) .
The disease showed a slowly progressive course. At 39 years of age, the patient presented further worsening of proximal lower limb weakness (MRC: tibialis anterior and gastrocnemius 0/5, quadriceps 3/5, iliopsoas 4/5), bilateral foot-drop and need of bilateral support during ambulation; however, the upper limbs were still spared.
Creatine Kinase (CK) levels at onset were increased (2000 U/l) and remained elevated over time at follow-up (407-1200 U/l). Electromyography (EMG) showed myopathic changes. No cardiac or respiratory involvement was detected. Electrocardiogram showed incomplete right bundle branch block and echocardiogram was normal. The patient did not show any cognitive impairment.
Two muscle biopsies were performed at age 22 and 30, respectively. Morphological examination was performed according to standard procedures [23] . The first muscle biopsy showed mild myopathic changes along with fibrosis. The second muscle biopsy in the left biceps brachii muscle revealed myopathic changes, type I fibre hypotrophy, multiple central nuclei, fibre splittings, rare cytoplasmic vacuoles, and lipid overload. Connective tissue was normal and no inflammatory infiltrates or necrosis were detected ( Fig. 2A) . Ultrastructural examination confirmed metabolic abnormalities characterised by a mild increase of intracellular lipids (Fig. 2E) . Immunohistochemical analysis showed normal signal for caveolin-3, dysferlin, dystrophin, merosin, α and γ-sarcoglycan. Glycolytic enzymes were normal despite of metabolic alterations shown at electron microscopy. In order to exclude a possible cause of distal myopathy, the Glucosamine (UDP-N-Acetyl)-2-Epimerase/NAcetylmannosamine Kinase (GNE) gene was analysed with normal results. The sample of the patient was further studied with Next Generation Sequencing (NGS) techniques. DNA samples underwent MotorPlex protocol, analysing the coding regions of 89 genes; 2 × 100 bp libraries were run on a HiSeq 1000 instrument (Illumina) and analysed through a custom pipeline of bioinformatics analyses [24, 25] . We detected predicted pathogenic variants in MYBPC3 (c.3589A > G; p.Thr1197Ala) and SYNE2 (c.976G > A; p.Asp326Asn) genes and a homozygous loss-of-function change in TCAP (c.90_91del) gene. Considering clinical and histological features of the patient, the most likely pathogenic change among these was in TCAP. In fact the clinical phenotypes associated with MYBPC3 and SYNE2 mutations, respectively autosomal dominant cardiomyopathy and autosomal dominant Emery-Dreifuss muscular dystrophy phenotype, were not consistent with the clinical presentation of our patient.
The mutation in TCAP gene is a homozygous 2 bp deletion in exon 1 which determines the frameshift of the transcript (p.Ser31HisfsX11). In order to confirm the inactivating effect of the mutation we performed immunostaining and Western blot analysis of telethonin using Rabbit polyclonal anti-TCAP antibodies (abCAM, ab121868 -Santa Cruz Biotechnology, Santa Cruz, CA). The analysis revealed complete absence of the protein with both methods (Fig. 2C; Fig. 3 ). Unfortunately parental DNA was not available to confirm the segregation of the mutation, but the consanguinity and functional null effect of the mutation both support the homozygous status.
Interestingly, the same variant has been recently identified [18] in a 35-year-old female patient of Turkish ethnicity with LGMD2G phenotype. In both cases, diagnosis was obtained by NGS approach. We revised the patient's NGS data for informative markers located 5′ and 3′ of the TCAP gene to investigate the presence of a possible founder effect. We identified a homozygous region extending at 3′ for 10 Mb including the SGCA gene (Suppl. Fig. S1 ). 
Discussion
LGMD2G is a very rare form of Limb girdle muscular dystrophy with autosomal recessive inheritance. To date, only 27 cases have been described, representing 15 independent patients, since in five families there was more than one affected person in the same generation (Table 1A -B). The majority of these patients were of Brazilian descent, and the c.157C > T (p.Gln53X -exon 2) mutation in homozygous state is the most frequent mutation. Although cases are rare worldwide, TCAP mutations are likely to occur in every continent.
Here we describe a frameshift mutation in the TCAP gene causing a proximo-distal myopathy, which had been detected by next generation sequencing techniques. The clinical phenotype was consistent with LGMD2G, and absence of telethonin at WB analysis confirmed the diagnosis.
Interestingly, the same mutation has been recently described in a 35-year-old Turkish girl with LGMD2G phenotype [18] . Markers reconstruction from NGS data in a 10 Mb genomic distance across the TCAP gene demonstrated an identical homozygous haplotype in these two patients, thus suggesting a possible founder effect for this recessive mutation.
The description of our new case further confirms that this mutation is associated with the milder spectrum of the disease, showing onset of weakness in adolescence. So far, the mean age of weakness onset in the literature had been described at 8.5 ± 9.2 years of age (Table 1A) , while the two patients with the c.90_91del mutation complained of weakness respectively at the age of 22 and 17 years. This mutation, as well as all of others described so far in other LGMD2G subjects, is a truncating one, while dominant missense mutations are described in cases of cardiomyopathy [19] . The position of the new stop codon created by the mutation seems not responsible for the phenotype, as well as the entity of protein reduction by Western blot analysis. Although preliminary, these data argue against a direct correlation between mutation type, residual muscle protein level and clinical phenotype, as far as age at disease onset is concerned. Other modulating factors might be involved in determining part of the clinical variability. Interestingly, tendon contractures and myalgia were not seen in our patient, while these symptoms already had appeared at a very young age (2 years of age) in the patient described by Ikenberg et al. [18] . Upper extremities were spared in both cases at last evaluation, respectively at 39 and 34 years, which is atypically mild for LGMD2G, since none of the patients previously described had a similar distribution at last evaluation.
On the contrary, distal involvement is frequently described in LGMD2G patients, sometimes also at early stages [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , especially in lower limbs, presenting with foot-drop and involvement of tibialis anterior muscles. In our patient, this feature was predominant also in other subjects with LGMD2G [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Respiratory involvement or cardiomyopathy was not reported in both cases, consistently with the majority of previous reports; extrasystolia had been described only in the Turkish patient. CK levels were similar to those detected in other patients (2-50×). Sparing of the sartorius muscle was seen in both muscle MRIs as described previously [12] [13] [14] 17] .
The muscle biopsy of our patient showed a pattern consistent with other cases of LGMD2G reported in literature, with type I fibre atrophy, central nuclei, fibre splittings and myopathic changes without connective tissue increase and normal sarcomeric structure [4, 9, 13] . We neither detected lobulated fibres nor classical rimmed vacuoles, as seen in other reports [4, 9, 13] . However, we detected rare cytoplasmic vacuoles and lipid overload, confirmed by ultrastructural examination showing metabolic abnormalities such as mild increase of intracellular lipids (Fig. 2E) .
Glycogen deposits and metabolic alterations were an atypical finding, since until now, focal intrasarcoplasmic glycogen deposits were only described once in LGMD2G [9] . This additional finding in our patient enlarges the morphological spectrum of the disease.
Conclusion
This case contributes to consolidate a typical phenotype of LGMD2G and further expands the clinical spectrum of LGMD2G, since it confirms that also milder forms of the disease may exists. Moreover it suggests a founder effect for the TCAP c.90_91del mutation. Although telethoninopathy is not a frequent cause of muscular dystrophy -in our previously described LGMD cohort [26] it accounts only to 1% of LGMD patients -it is useful to consider this form of LGMD in the differential diagnosis, especially in patients presenting with distal involvement of the lower limbs. Interestingly, the muscle biopsy of our patient presented some atypical features, expanding the morphological spectrum of the disease. 
